AU3069097A - Inhibitors of pseudonomas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients - Google Patents

Inhibitors of pseudonomas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients

Info

Publication number
AU3069097A
AU3069097A AU30690/97A AU3069097A AU3069097A AU 3069097 A AU3069097 A AU 3069097A AU 30690/97 A AU30690/97 A AU 30690/97A AU 3069097 A AU3069097 A AU 3069097A AU 3069097 A AU3069097 A AU 3069097A
Authority
AU
Australia
Prior art keywords
treatments
inhibitors
compositions
cystic fibrosis
fibrosis patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30690/97A
Inventor
Carole Basbaum
Jim Gum
Young S. Kim
Jian Dong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU3069097A publication Critical patent/AU3069097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU30690/97A 1996-05-15 1997-05-15 Inhibitors of pseudonomas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients Abandoned AU3069097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1772096P 1996-05-15 1996-05-15
US60017720 1996-05-15
PCT/US1997/008310 WO1997043643A1 (en) 1996-05-15 1997-05-15 Inhibitors of pseudomonas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients

Publications (1)

Publication Number Publication Date
AU3069097A true AU3069097A (en) 1997-12-05

Family

ID=21784178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30690/97A Abandoned AU3069097A (en) 1996-05-15 1997-05-15 Inhibitors of pseudonomas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients

Country Status (2)

Country Link
AU (1) AU3069097A (en)
WO (1) WO1997043643A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
WO1998040090A1 (en) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methods for inhibiting bacterial cytotoxicity
WO1999041270A1 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Compositions and methods for the inhibition of muc-5 mucin gene expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012892A1 (en) * 1989-04-14 1990-11-01 The Regents Of The University Of California Human intestinal mucin
WO1991008217A1 (en) * 1989-12-05 1991-06-13 The Regents Of The University Of California Human intestinal mucins
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal

Also Published As

Publication number Publication date
WO1997043643A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
AU2002211379A1 (en) Compositions and methods for treatment of cystic fibrosis
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
AU3686695A (en) Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
AU5622198A (en) Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
AU2370395A (en) Game of skill and chance
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU1751795A (en) Liposome compositions and methods for the treatment of atherosclerosis
AU5315898A (en) Compositions for disinfection of skin and mucous membrane
AU4224600A (en) Composition and method for treatment of inflammation and pain in mammals
AU5814096A (en) Composition comprising amoxycillin and clavulanic acid
AU2180097A (en) Composition for prevention and treatment of periodontal diseases
AU2542097A (en) Oligonucleotide treatments and compositions for human melanoma
AU9016898A (en) Methods and compositions for treatment of restenosis
AU1734895A (en) Methods and compositions for treatment of periodontal disease and repair of periodontal lesions
AU3541595A (en) Method and composition for treating cystic fibrosis
AU5693696A (en) Use of glyceryl triacetate for treatment of onychomycoses
AU2036297A (en) Topical formulations of aciclovir
AU6766900A (en) Cd39/ecto-adpase for treatment of thrombotic and ischemic disorders
AU1331399A (en) Preparation for prevention and healing of inflammation affections
AUPO359396A0 (en) A method of treatment and pharmaceutical compositions useful for same
AU3069097A (en) Inhibitors of pseudonomas aeruginosa induced mucin production: compositions and treatments for cystic fibrosis patients
AU1249395A (en) Topical treatment of ocular photophobia
AU6704396A (en) Compositions for treating sunburn and oral hygiene problems
EP0750511A4 (en) Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor